Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	274.82	127.98	191.44	113.56	144.9	287.31
Short-Term Investments	82.51	88.92	9.95	116.04	74.92	-
Cash & Short-Term Investments	357.32	216.9	201.39	229.6	219.81	287.31
Cash Growth	100.09%	7.70%	-12.28%	4.45%	-23.49%	29.14%
Other Receivables	0.61	0.7	0.06	0.59	0.13	0.01
Receivables	0.61	0.7	0.06	0.59	0.13	0.01
Prepaid Expenses	12.69	11.12	11.32	10.93	6.94	6.44
Restricted Cash	0.08	0.08	-	-	-	-
Other Current Assets	5.04	3.97	2.56	2.96	2.33	0.18
Total Current Assets	375.74	232.76	215.34	244.07	229.22	293.93
Property, Plant & Equipment	7.44	8.25	12.43	11.43	9.08	3.79
Long-Term Investments	22.99	29.82	-	-	-	-
Other Long-Term Assets	0.72	0.72	0.57	0.57	0.57	0.21
Total Assets	406.89	271.56	228.34	256.07	238.87	297.93
Accounts Payable	2.19	2.5	1.7	0.77	2.39	1.5
Accrued Expenses	24.34	15.49	10.9	12.88	12.71	8.41
Current Portion of Leases	-	2.32	2.06	2.36	1.51	1.07
Current Unearned Revenue	18.16	18.99	15.31	14.88	-	-
Other Current Liabilities	-	0.75	0.86	0.51	0.54	0.46
Total Current Liabilities	44.69	40.06	30.82	31.39	17.14	11.43
Long-Term Leases	1.87	2.45	4.77	2.72	3.53	0.08
Long-Term Unearned Revenue	10.26	-	33.07	36.86	-	-
Other Long-Term Liabilities	-	0.03	0.11	0.25	0.42	0.34
Total Liabilities	56.81	42.53	68.78	71.22	21.09	11.85
Common Stock	0.01	0.01	0.01	0	0	0
Additional Paid-In Capital	728.12	720	561.43	483.17	414.02	396.35
Retained Earnings	-377.95	-490.83	-401.85	-297.15	-196.08	-110.28
Comprehensive Income & Other	-0.1	-0.15	-0.02	-1.18	-0.17	-
Total Common Equity	350.07	229.02	159.57	184.85	217.78	286.08
Shareholders' Equity	350.07	229.02	159.57	184.85	217.78	286.08
Total Liabilities & Equity	406.89	271.56	228.34	256.07	238.87	297.93
Total Debt	1.87	4.77	6.84	5.08	5.04	1.15
Net Cash (Debt)	378.44	241.95	194.56	224.52	214.77	286.16
Net Cash Growth	119.71%	24.36%	-13.34%	4.54%	-24.95%	28.63%
Net Cash Per Share	6.56	4.48	4.42	5.77	5.85	8.55
Filing Date Shares Outstanding	54.6	54.08	46.3	44.15	37.36	36.66
Total Common Shares Outstanding	54.6	54.03	45.92	39.44	36.9	36.58
Working Capital	331.05	192.7	184.52	212.68	212.08	282.51
Book Value Per Share	6.41	4.24	3.47	4.69	5.90	7.82
Tangible Book Value	350.07	229.02	159.57	184.85	217.78	286.08
Tangible Book Value Per Share	6.41	4.24	3.47	4.69	5.90	7.82
Machinery	-	10.31	10.14	8.57	4.93	4.15
Construction In Progress	-	0.12	0.07	0.45	1.61	0.01
Leasehold Improvements	-	2.33	2.29	1.87	0.26	0.21

Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q